{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
dopamine
to a specific field?
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
CP 226269 is a selective dopamine D4 agonist. This compound was developed by Pfizer for Neuroscience research. CP226269 showed a significant enhancement in the 5-trial inhibitory avoidance model.
Status:
Other
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
SB-277011 is a potent and selective dopamine D(3) receptor antagonist. SB-277011 attenuates reinforcing propertes of drugs of abuse incluting opiates, cocaine, methamphetamine, nicotine and ethanol. SB-277011A produced a significant decrease in food intake in obese rats. Clinical development of SB-277011A has been halted by GlaxoSmithKline Pharmaceuticals, due to poor bioavailability (~2%) and a very short half-life (<20 min) in primates.
